Literature DB >> 20980521

Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2-restricted HIV-Gag (SLYNTVATL) and HCV-NS5b (ALYDVVSKL) epitopes in individuals infected with human immunodeficiency and hepatitis C viruses.

Bahareh Vali1, Robert Tohn, Michael J Cohen, Ali Sakhdari, Prameet M Sheth, Feng Yun Yue, David Wong, Colin Kovacs, Rupert Kaul, Mario A Ostrowski.   

Abstract

The immunologic mechanisms underlying the faster progression of hepatitis C virus (HCV) disease in the presence of human immunodeficiency virus (HIV) coinfection are not clearly understood. T-cell cross-reactivity between HCV and influenza virus-specific epitopes has been associated with rapid progression of HCV disease (S. Urbani, B. Amadei, P. Fisicaro, M. Pilli, G. Missale, A. Bertoletti, and C. Ferrari, J. Exp. Med. 201:675-680, 2005). We asked whether T-cell cross-reactivity between HCV and HIV could exist during HCV/HIV coinfection and affect pathogenesis. Our search for amino acid sequence homology between the HCV and HIV proteomes revealed two similar HLA-A2-restricted epitopes, HIV-Gag (SLYNTVATL [HIV-SL9]) and HCV-NS5b (ALYDVVSKL [HCV-AL9]). We found that 4 out of 20 HLA-A2-positive (HLA-A2(+)) HIV-infected individuals had CD8(+) T cells that recognized both the HIV-SL9 and HCV-AL9 epitopes. However, the AL9 epitope was generally shown to be a weak agonist. Although HCV-monoinfected individuals in our study did not show AL9-specific responses, we found that about half of HCV/HIV-coinfected individuals had dual responses to both epitopes. High dual T-cell recognition among coinfected subjects was usually due to separate T-cell populations targeting each epitope, as determined by pentamer staining. The one individual demonstrating cross-reactive T cells to both epitopes showed the most advanced degree of liver disease. In coinfected individuals, we observed a positive correlation between the magnitudes of T-cell responses to both the SL9 and the AL9 epitopes, which was also positively associated with the clinical parameter of liver damage. Thus, we find that HIV infection induces T cells that can cross-react to heterologous viruses or prime for T cells that are closely related in sequence. However, the induction of cross-reactive T cells may not be associated with control of disease caused by the heterologous virus. This demonstrates that degeneracy of HIV-specific T cells may play a role in the immunopathology of HCV/HIV coinfection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20980521      PMCID: PMC3014184          DOI: 10.1128/JVI.01743-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens.

Authors:  Michael A Brehm; Amelia K Pinto; Keith A Daniels; Jonathan P Schneck; Raymond M Welsh; Liisa K Selin
Journal:  Nat Immunol       Date:  2002-06-03       Impact factor: 25.606

2.  Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon.

Authors:  Weisan Chen; Kelly-Anne Masterman; Sameh Basta; S M Mansour Haeryfar; Nektaria Dimopoulos; Barbara Knowles; Jack R Bennink; Jonathan W Yewdell
Journal:  Eur J Immunol       Date:  2004-01       Impact factor: 5.532

3.  The multiple mechanisms of T cell receptor cross-reactivity.

Authors:  Yiyuan Yin; Roy A Mariuzza
Journal:  Immunity       Date:  2009-12-18       Impact factor: 31.745

4.  Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis.

Authors:  Shalyn C Clute; Levi B Watkin; Markus Cornberg; Yuri N Naumov; John L Sullivan; Katherine Luzuriaga; Raymond M Welsh; Liisa K Selin
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

5.  Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses.

Authors:  L K Selin; M Y Lin; K A Kraemer; D M Pardoll; J P Schneck; S M Varga; P A Santolucito; A K Pinto; R M Welsh
Journal:  Immunity       Date:  1999-12       Impact factor: 31.745

6.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.

Authors:  C S Graham; L R Baden; E Yu; J M Mrus; J Carnie; T Heeren; M J Koziel
Journal:  Clin Infect Dis       Date:  2001-07-06       Impact factor: 9.079

Review 7.  Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.

Authors:  Hla-Hla Thein; Qilong Yi; Gregory J Dore; Murray D Krahn
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

8.  The utility of aspartate aminotransferase/platelet ratio index in HIV/hepatitis C-co-infected patients.

Authors:  Lalita Shastry; Tina Wilson; Steven Lascher; Jill A Nord
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

9.  Heterologous T cell immunity in severe hepatitis C virus infection.

Authors:  Simona Urbani; Barbara Amadei; Paola Fisicaro; Massimo Pilli; Gabriele Missale; Antonio Bertoletti; Carlo Ferrari
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

10.  Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations.

Authors:  L K Selin; S M Varga; I C Wong; R M Welsh
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more
  8 in total

Review 1.  Cross-reactivity of T cells and its role in the immune system.

Authors:  Galina Petrova; Andrea Ferrante; Jack Gorski
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

2.  Cross-Reactivity against Multiple HIV-1 Epitopes Is Characteristic of HIV-1-Specific Cytotoxic T Lymphocyte Clones.

Authors:  Arumugam Balamurugan; Hwee L Ng; Otto O Yang
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

3.  HIV-Specific CD8(+) T Lymphocytes in Blood of Long-Term HIV-Infected Hemophilia Patients.

Authors:  Volker Daniel; Sabine Scherer; Mahmoud Sadeghi; Peter Terness; Angela Huth-Kühne; Gerhard Opelz
Journal:  Biores Open Access       Date:  2013-12-01

4.  Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses.

Authors:  Christopher W Pohlmeyer; Sarah B Laskey; Sarah E Beck; Daniel C Xu; Adam A Capoferri; Caroline C Garliss; Megan E May; Alison Livingston; Walt Lichmira; Richard D Moore; M Sue Leffell; Nicholas J Butler; Jennifer E Thorne; John A Flynn; Robert F Siliciano; Joel N Blankson
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

5.  SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.

Authors:  Annika Nelde; Tatjana Bilich; Jonas S Heitmann; Yacine Maringer; Helmut R Salih; Malte Roerden; Maren Lübke; Jens Bauer; Jonas Rieth; Marcel Wacker; Andreas Peter; Sebastian Hörber; Bjoern Traenkle; Philipp D Kaiser; Ulrich Rothbauer; Matthias Becker; Daniel Junker; Gérard Krause; Monika Strengert; Nicole Schneiderhan-Marra; Markus F Templin; Thomas O Joos; Daniel J Kowalewski; Vlatka Stos-Zweifel; Michael Fehr; Armin Rabsteyn; Valbona Mirakaj; Julia Karbach; Elke Jäger; Michael Graf; Lena-Christin Gruber; David Rachfalski; Beate Preuß; Ilona Hagelstein; Melanie Märklin; Tamam Bakchoul; Cécile Gouttefangeas; Oliver Kohlbacher; Reinhild Klein; Stefan Stevanović; Hans-Georg Rammensee; Juliane S Walz
Journal:  Nat Immunol       Date:  2020-09-30       Impact factor: 25.606

6.  Expansion of Unique Hepatitis C Virus-Specific Public CD8+ T Cell Clonotypes during Acute Infection and Reinfection.

Authors:  Sabrina Mazouz; Maude Boisvert; Mohamed S Abdel-Hakeem; Omar Khedr; Julie Bruneau; Naglaa H Shoukry
Journal:  J Immunol       Date:  2021-08-02       Impact factor: 5.426

Review 7.  Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development.

Authors:  Kathrin Balz; Lilith Trassl; Valerie Härtel; Philipp P Nelson; Chrysanthi Skevaki
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

Review 8.  Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection.

Authors:  Muhammad Bilal Latif; Sudhanshu Shukla; Perla Mariana Del Rio Estrada; Susan Pereira Ribeiro; Rafick Pierre Sekaly; Ashish Arunkumar Sharma
Journal:  Transl Res       Date:  2021-12-03       Impact factor: 7.012

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.